Skip to content
Screener

Discontinued — last reported Q4 '21

Free cash flow at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$3.09B-13.2%
Gilead Sciences logo
Gilead SciencesGILD
$3.43B+377%
AbbVie logo
AbbVieABBV
$3.56B+155%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
-$16.99M-118%
LQD
Liquidia CorporationLQDA
$69.01M+270%
United Therapeutics logo
United TherapeuticsUTHR
$205.6M+58.8%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-

Valuation

See full
Market cap$60.57M+119%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Calculated from Rein Therapeutics Inc.’s reported figures.

The source filing: Rein Therapeutics Inc.’s 10-K, filed March 20, 2023. Open the filing →

Filed
Mar 20, 2023
Fiscal year
FY2021
Accession
0000950170-23-008767

FAQ

What is Rein Therapeutics Inc.'s free cash flow?
Rein Therapeutics Inc. (RNTX) reported free cash flow of -$6.26M in Q4 2021.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.

Ask your AI about Rein Therapeutics Inc.'s free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude